Sun Pharmaceutical Industries Limited Statistics
Want to see IN:SUNPHARMA full AI Analyst Report?
Sun Pharmaceutical Industries Limited (SUNPHARMA) Stock Statistics & Valuation Metrics
Total Valuation
Sun Pharmaceutical Industries Limited has a market cap or net worth of INR 4.49T. The enterprise value is INR 4.07T.
- Market Cap
- INR 4.49T
- Enterprise Value
- INR 4.07T
Share Statistics
Sun Pharmaceutical Industries Limited has 2,399,278,300 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 2,399,278,300
- Owned by Insiders
- ―
- Owned by Institutions
- 7.04%
Financial Efficiency
Sun Pharmaceutical Industries Limited’s return on equity (ROE) is 0.14 and return on invested capital (ROIC) is 11.46%.
- Return on Equity (ROE)
- 0.14
- Return on Assets (ROA)
- 0.11
- Return on Invested Capital (ROIC)
- 11.46%
- Return on Capital Employed (ROCE)
- 0.16
- Revenue Per Employee
- 12.44M
- Profits Per Employee
- 2.44M
- Employee Count
- 47,000
- Asset Turnover
- 0.54
- Inventory Turnover
- 2.25
Valuation Ratios
The current PE Ratio of Sun Pharmaceutical Industries Limited is 40.95. Sun Pharmaceutical Industries Limited’s PEG ratio is 8.50.
- PE Ratio
- 40.95
- PS Ratio
- 7.29
- PB Ratio
- 5.03
- Price to FCF
- 0.00
- Price to Operating Cash Flow
- 0.00
- PEG Ratio
- 8.50
Income Statement
In the last 12 months, Sun Pharmaceutical Industries Limited had revenue of 584.62B and earned 114.79B in profits. Earnings per share was 47.80.
- Revenue
- 584.62B
- Gross Profit
- 325.62B
- Operating Income
- 135.53B
- Pretax Income
- 150.63B
- Net Income
- 114.79B
- EBITDA
- 183.40B
- Earnings Per Share (EPS)
- 47.80
Cash Flow
In the last 12 months, operating cash flow was 0 and capital expenditures 0, giving a free cash flow of 0 billion.
- Operating Cash Flow
- 0
- Free Cash Flow
- 0
- Free Cash Flow per Share
- 0.00
Dividends & Yields
Sun Pharmaceutical Industries Limited pays an annual dividend of INR 5.00, resulting in a dividend yield of 0.85%
- Dividend Per Share
- INR 5.00
- Dividend Yield
- 0.85%
- Payout Ratio
- 31.37%
- Free Cash Flow Yield
- 0.00%
- Earnings Yield
- 2.44%
Stock Price Statistics
- Beta
- 0.49
- 52-Week Price Change
- 6.40%
- 50-Day Moving Average
- 1813.21
- 200-Day Moving Average
- 1821.81
- Relative Strength Index (RSI)
- 62.40
- Average Volume (3m)
- 106.08K
Important Dates
Sun Pharmaceutical Industries Limited upcoming earnings date is Feb 04, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 30, 2026
- Next Earnings Date
- Feb 04, 2027
- Ex-Dividend Date
- Jul 07, 2026
Financial Position
Sun Pharmaceutical Industries Limited as a current ratio of 2.82, with Debt / Equity ratio of 5.54%
- Current Ratio
- 2.82
- Quick Ratio
- 2.31
- Debt to Market Cap
- 0.01
- Net Debt to EBITDA
- -0.38
- Interest Coverage Ratio
- 39.99
Taxes
In the past 12 months, Sun Pharmaceutical Industries Limited has paid 35.54B in taxes.
- Income Tax
- 35.54B
- Effective Tax Rate
- 0.24
Enterprise Valuation
Sun Pharmaceutical Industries Limited EV to EBITDA ratio is 23.50, with an EV/FCF ratio of 0.00.
- EV to Sales
- 7.01
- EV to EBITDA
- 23.50
- EV to Free Cash Flow
- 0.00
- EV to Operating Cash Flow
- 0.00
Balance Sheet
Sun Pharmaceutical Industries Limited has INR 335.70B in cash and marketable securities with INR 32.41B in debt, giving a net cash position of INR 303.29B billion.
- Cash & Marketable Securities
- INR 335.70B
- Total Debt
- INR 32.41B
- Net Cash
- INR 303.29B
- Net Cash Per Share
- INR 126.41
- Tangible Book Value Per Share
- INR 273.39
Margins
Gross margin is 55.92%, with operating margin of 23.17%, and net profit margin of 17.79%.
- Gross Margin
- 55.92%
- Operating Margin
- 23.17%
- Pretax Margin
- 24.32%
- Net Profit Margin
- 17.79%
- EBITDA Margin
- 29.82%
- EBIT Margin
- 24.94%
Analyst Forecast
The average price target for Sun Pharmaceutical Industries Limited is INR 2,025.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- INR 2,025.00
- Price Target Upside
- 8.16% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 2
- Revenue Growth Forecast
- 12.13%
- EPS Growth Forecast
- 4.94%
Scores
- Smart Score
- ―
- AI Score
- 69

